The Chemours Company walks into its Q1 2026 earnings report with one of the sharpest momentum stories in the chemicals sector — up 30% in a month — and options traders who appear to be chasing the move rather than hedging against a reversal.
The most striking signal heading into today's print is how one-sided the options market has become. The put/call ratio has collapsed to 0.25, well below its 20-day average of 0.30 and close to its 52-week low of 0.21. That is the mirror image of a defensive posture — call demand is heavily outpacing put buying. The 30% rally from below $22 to $27.94 has been accompanied by rising call interest, not rising caution, which points to a market that has been adding bullish exposure through the run-up.
Short sellers are not pushing back hard. Short interest holds at roughly 6.2% of the free float — meaningful but well off the peaks seen in early April when it ran above 7%. Over the past month, short positions fell about 10%, even as the stock surged. Borrow remains trivially cheap at 0.41% annualised. Availability is wide open — the lending market has no grip here. The ORTEX short score of 41 sits in the lower half of its recent range, confirming there is no escalating short thesis.
The analyst community has been consistently lifting targets through 2026. Truist raised to $30 just last week, and UBS moved to $29 in April — both maintaining Buy ratings. The consensus mean target of $23.22 now sits below the current price, meaning the stock has outrun the Street's formal targets. Goldman remains cautious with a Neutral rating and a target that the stock has already cleared. Bulls point to pricing power in Chemours' portfolio, the ongoing "Pathway to Thrive" cost-reduction plan targeting $250M+ in savings through 2027, and improved TiO2 margins. Bears focus on HFC/HFO demand pressures from regulatory shifts, capacity additions in titanium dioxide, and macro softness in housing and auto end-markets. The EV/EBITDA multiple has compressed about 0.3x over the past month despite the price rally, suggesting earnings expectations are rising alongside the stock.
Peers have broadly participated in the week's chemical-sector bounce — TROX and KRO each gained around 7-8%, HUN nearly 10% — meaning Chemours' move is a sector story as much as a company-specific one. The Q1 print will test whether the operational improvement narrative — particularly in TiO2 margin recovery and cost savings delivery — can validate a multiple that has repriced sharply ahead of results.
See the live data behind this article on ORTEX.
Open CC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
